1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6937F7D39A4D6EF5B85256E4500756D26
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/managing-cross-functional-pharmaceutical-launch-teams?opendocument
18
19opendocument
2018.205.96.39
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Product Launch Product Launch Excellence

Managing Cross-Functional Pharmaceutical Launch Teams

DB Image

ID: 4568


Features:

Metrics, Graphics, Summary Matrix, Detailed Process Map


Pages/Slides: 17


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Leading pharmaceutical companies have learned that team management is a complex process. Launch teams must be able to utilize resources and expertise within the company, sustain a coherent approach through transitions, and prepare products for a successful launch.

This 17-page document details how creating an effective launch team is imperative to ensuring the success of a new product’s launch. Cross-functional launch teams can use this information to execute a drug development plan that can shape a compound into a commercially successful product for the company.

Key topics covered in this document include:
-Incentives and Support
-Launch Team Structure
-Ongoing Marketing Activities

Select best practices include:
1. Create a cross-functional launch team to ensure a seamless product rollout.
- Various benchmark partners employ cross-functional teams to effectively launch new products. Most have a unique team comprised of eight to nine members within each launch country.
2. Align incentives to encourage cross-functional cooperation.
- One benchmark partner is beginning to see a more unified approach to development from the clinical and commercial sides by aligning clinical and commercial’s compensation, bonuses and evaluation.
3. Use a variety of financial and strategic factors to determine product ranking within the company portfolio.
- One benchmark partner has an extensive annual portfolio planning process that involves ranking all drugs in early stage discovery to Phase III development, by order of importance and allocation level.

This research originated from a Best Practices, LLC consulting project.

Industries Profiled:
Pharmaceutical; Health Care; Biotech; Medical Device


Companies Profiled:
Merck; Sanofi-aventis; Eli Lilly; GlaxoSmithKline; Novartis; Pfizer; Johnson & Johnson; Bristol-Myers Squibb; AstraZeneca; Roche; Schering-Plough

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.